Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone

Sanghoon Lee, Sinan Ozkavukcu, Elke Heytens, Fred Moy, Rose M. Alappat, Kutluk Oktay

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC). Methods: The correlation between AMH and AFC and ECC outcomes were analyzed retrospectively on forty one women with breast cancer before adjuvant treatment. Results: AMH and AFC had a stronger correlation with the total number of oocytes and the number of mature oocytes than age, FSH, and inhibin B. Subjects were evaluated by the number of mature oocytes retrieved to create cutoff points of AMH level, which identified 1.2 ng/mL as a potential value. Seven of 18 patients with AMH levels ≤1.2 ng/mL had low response versus none of 23 with >1.2 ng/mL, (p=0.001). Conclusions: AMH is the most reliable serum marker of ECC outcomes, together with AFC as a biophysical marker, in breast cancer patients. Low response is highly likely when the AMH level is ≤1.2 ng/mL.

Original languageEnglish
Pages (from-to)651-656
Number of pages6
JournalJournal of Assisted Reproduction and Genetics
Volume28
Issue number7
DOIs
Publication statusPublished - 2011 Jul 1
Externally publishedYes

Fingerprint

letrozole
Anti-Mullerian Hormone
Cryopreservation
Follicle Stimulating Hormone
Oocytes
Embryonic Structures
Breast Neoplasms
Fertility Preservation
Antral

Keywords

  • Anti-Mullerian hormone (AMH)
  • Breast cancer
  • Cryopreservation
  • Fertility preservation
  • Letrozole

ASJC Scopus subject areas

  • Reproductive Medicine
  • Genetics
  • Obstetrics and Gynaecology
  • Developmental Biology
  • Genetics(clinical)

Cite this

Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. / Lee, Sanghoon; Ozkavukcu, Sinan; Heytens, Elke; Moy, Fred; Alappat, Rose M.; Oktay, Kutluk.

In: Journal of Assisted Reproduction and Genetics, Vol. 28, No. 7, 01.07.2011, p. 651-656.

Research output: Contribution to journalArticle

@article{0c1b87db3feb4650b49fd6c4f9f59e15,
title = "Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone",
abstract = "Purpose: To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC). Methods: The correlation between AMH and AFC and ECC outcomes were analyzed retrospectively on forty one women with breast cancer before adjuvant treatment. Results: AMH and AFC had a stronger correlation with the total number of oocytes and the number of mature oocytes than age, FSH, and inhibin B. Subjects were evaluated by the number of mature oocytes retrieved to create cutoff points of AMH level, which identified 1.2 ng/mL as a potential value. Seven of 18 patients with AMH levels ≤1.2 ng/mL had low response versus none of 23 with >1.2 ng/mL, (p=0.001). Conclusions: AMH is the most reliable serum marker of ECC outcomes, together with AFC as a biophysical marker, in breast cancer patients. Low response is highly likely when the AMH level is ≤1.2 ng/mL.",
keywords = "Anti-Mullerian hormone (AMH), Breast cancer, Cryopreservation, Fertility preservation, Letrozole",
author = "Sanghoon Lee and Sinan Ozkavukcu and Elke Heytens and Fred Moy and Alappat, {Rose M.} and Kutluk Oktay",
year = "2011",
month = "7",
day = "1",
doi = "10.1007/s10815-011-9567-z",
language = "English",
volume = "28",
pages = "651--656",
journal = "Journal of Assisted Reproduction and Genetics",
issn = "1058-0468",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone

AU - Lee, Sanghoon

AU - Ozkavukcu, Sinan

AU - Heytens, Elke

AU - Moy, Fred

AU - Alappat, Rose M.

AU - Oktay, Kutluk

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Purpose: To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC). Methods: The correlation between AMH and AFC and ECC outcomes were analyzed retrospectively on forty one women with breast cancer before adjuvant treatment. Results: AMH and AFC had a stronger correlation with the total number of oocytes and the number of mature oocytes than age, FSH, and inhibin B. Subjects were evaluated by the number of mature oocytes retrieved to create cutoff points of AMH level, which identified 1.2 ng/mL as a potential value. Seven of 18 patients with AMH levels ≤1.2 ng/mL had low response versus none of 23 with >1.2 ng/mL, (p=0.001). Conclusions: AMH is the most reliable serum marker of ECC outcomes, together with AFC as a biophysical marker, in breast cancer patients. Low response is highly likely when the AMH level is ≤1.2 ng/mL.

AB - Purpose: To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC). Methods: The correlation between AMH and AFC and ECC outcomes were analyzed retrospectively on forty one women with breast cancer before adjuvant treatment. Results: AMH and AFC had a stronger correlation with the total number of oocytes and the number of mature oocytes than age, FSH, and inhibin B. Subjects were evaluated by the number of mature oocytes retrieved to create cutoff points of AMH level, which identified 1.2 ng/mL as a potential value. Seven of 18 patients with AMH levels ≤1.2 ng/mL had low response versus none of 23 with >1.2 ng/mL, (p=0.001). Conclusions: AMH is the most reliable serum marker of ECC outcomes, together with AFC as a biophysical marker, in breast cancer patients. Low response is highly likely when the AMH level is ≤1.2 ng/mL.

KW - Anti-Mullerian hormone (AMH)

KW - Breast cancer

KW - Cryopreservation

KW - Fertility preservation

KW - Letrozole

UR - http://www.scopus.com/inward/record.url?scp=80052401056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052401056&partnerID=8YFLogxK

U2 - 10.1007/s10815-011-9567-z

DO - 10.1007/s10815-011-9567-z

M3 - Article

C2 - 21573682

AN - SCOPUS:80052401056

VL - 28

SP - 651

EP - 656

JO - Journal of Assisted Reproduction and Genetics

JF - Journal of Assisted Reproduction and Genetics

SN - 1058-0468

IS - 7

ER -